| 引用本文: | 蓝小雯,黎洪棉,黄晓,王超群,李富林,林文贤,赖仲宏,徐房添,黎海业.关节腔内注射浓缩生长因子治疗膝骨关节炎的临床效果及安全性观察[J].中国临床新医学,0,():-. |
| lan xiaowen.关节腔内注射浓缩生长因子治疗膝骨关节炎的临床效果及安全性观察[J].中国临床新医学,0,():-. |
|
| 本文已被：浏览 2次 下载 0次 |
|
|
|
| 关节腔内注射浓缩生长因子治疗膝骨关节炎的临床效果及安全性观察 |
|
蓝小雯1, 黎洪棉1, 黄晓1, 王超群1, 李富林1, 林文贤1, 赖仲宏2, 徐房添2, 黎海业1
|
|
1.广西壮族自治区人民医院;2.赣南医科大学第一附属医院骨科
|
|
| 摘要: |
| 目的 观察关节腔内注射浓缩生长因子（CGF）治疗膝骨关节炎（KOA）的临床效果及安全性。方法 回顾性分析2018年1月至2024年12月广西壮族自治区人民医院收治的253例KOA患者的临床资料，其中122例接受关节腔内注射CGF治疗者为观察组，另131接受关节腔内注射玻璃酸钠（HA）治疗者为对照组。比较两组治疗前（T0）及治疗后3个月（T3）、6个月（T6）的疼痛严重程度[视觉模拟量表（VAS）评分]及膝关节功能情况（WOMAC评分及Lysholm膝关节活动评分）。比较两组治疗后6个月内KOA复发率。观察治疗期间及随访期间不良反应发生情况。结果 在治疗后，两组VAS评分、WOMAC评分均呈显著下降趋势（P＜0.05），Lysholm膝关节活动评分呈显著上升趋势（P＜0.05）。在T3、T6时间点，观察组VAS评分、WOMAC评分低于对照组，Lysholm膝关节活动评分高于HA组，差异有统计学意义（P＜0.05）。在治疗6个月内，观察组KOA复发率显著低于对照组(9.84% vs 51.91%;χ2=51.714,P＜0.001)。观察组和对照组分别有13例（10.66%）和18例（13.74%）报告注射部位有轻微的疼痛或肿胀，均自行缓解。两组治疗及随访期间均未发现严重不良事件。结论 关节腔内注射CGF治疗 KOA可取得良好的临床效果，且复发率低、安全性好，值得临床推荐。 |
| 关键词: 浓缩生长因子 玻璃酸钠 关节内注射 膝骨关节炎 临床疗效 |
| DOI： |
| 分类号: |
| 基金项目:国家自然科学基金项目（编号:82260433）；广西科技重大专项项目(编号:桂科 AA23023004) ；广西自然科学基金重点项目（编号:2023GXNSFDA026035）； |
|
| Clinical Efficacy And Safety Observation Of Intra-Articular Injection Of Concentrated Growth Factor In The Treatment Of Knee Osteoarthritis |
|
lan xiaowen
|
|
Guangxi Zhuang Autonomous Region People’s Hospital
|
| Abstract: |
| Objective To evaluate the clinical efficacy and safety of concentrated growth factor (CGF) intra-articular injections for the treatment of knee osteoarthritis (KOA). Methods A retrospective analysis was conducted on the clinical data of 253 patients with KOA admitted to the Guangxi Zhuang Autonomous Region People’s Hospital from January 2018 to December 2024. Among them, 122 patients who received intra-articular CGF injections were assigned to the observation group, while 131 patients who received intra-articular sodium hyaluronate (HA) injections were assigned to the control group. We compared pain severity [Visual Analogue Scale (VAS) scores] and knee function (WOMAC scores and Lysholm Knee Score) between the two groups at baseline (T0) and 3 months (T3) and 6 months (T6) post-treatment. We also compared the recurrence rates of KOA within 6 months post-treatment between the two groups. The incidence of adverse reactions during the treatment and follow-up periods was observed. Results After treatment, both groups showed a significant downward trend in VAS and WOMAC scores (P < 0.05) and a significant upward trend in the Lysholm Knee Range of Motion Score (P < 0.05). At time points T3 and T6, the VAS and WOMAC scores in the observation group were lower than those in the control group, while the Lysholm Knee Score was higher than that in the HA group, with statistically significant differences (P < 0.05). Within 6 months of treatment, the recurrence rate of KOA in the observation group was significantly lower than that in the control group (9.84% vs. 51.91%; χ2 = 51.714, P < 0.001). Thirteen patients (10.66%) in the observation group and 18 patients (13.74%) in the control group reported mild pain or swelling at the injection site, both of which resolved spontaneously. No serious adverse events were observed in either group during treatment or follow-up. Conclusion Intra-articular injection of CGF for the treatment of KOA yields good clinical outcomes, with a low recurrence rate and good safety profile, and is worthy of clinical recommendation. |
| Key words: Concentrated Growth Factor Hyaluronan Intra-articular injection Knee Osteoarthritis Clinical efficacy |
